UPDATE

AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS

Retrieved on: 
금요일, 5월 31, 2024
Scientific Advisory Group, UPDATE, CHMP, GCP, Safety, ALS, Peripheral nervous system, Good, Masitinib, EMA, Euronext, Microglia, Science, Health Canada, AFL, EAE, Guideline, B cell, Quality of life, Central nervous system, Euronext Paris, Vaccine

SUMMARY OF THE WEBCAST HELD ON MAY 30, 2024, PROVIDING AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS

Key Points: 
  • SUMMARY OF THE WEBCAST HELD ON MAY 30, 2024, PROVIDING AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS
    AB Science SA (Euronext - FR0010557264 - AB) is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in the treatment of amyotrophic lateral sclerosis (ALS).
  • These issues and main justifications presented by AB Science are detailed in the presentation.
  • The EMA decision will be made public during the next CHMP meeting to be held on June 24-27, 2024.
  • AB Science has asked to Euronext Paris to resume listing of its shares from the opening of trading on Monday June 03, 2024.

Almonty Closes Additional Tranches of Private Placement

Retrieved on: 
토요일, 4월 20, 2024
Mining, Minerals, Natural Resources, Tungsten, Sale, Moly, Person, ALI, News, Risk, Private, CDN, TSX, Multilateral, UPDATE, ANY, AII, Acquisition, APT, THIS, Minority, CDI, Placement

Lewis Black, Mark Trachuk, Daniel D’Amato and Andrew Ryu (the “Insiders”) participated in the private placement and, as such, the private placement is considered a related party transaction within the meaning of Multilateral Instrument 61-101– Protection of Minority Security Holders in Special Transactions (“MI 61-101”).

Key Points: 
  • Lewis Black, Mark Trachuk, Daniel D’Amato and Andrew Ryu (the “Insiders”) participated in the private placement and, as such, the private placement is considered a related party transaction within the meaning of Multilateral Instrument 61-101– Protection of Minority Security Holders in Special Transactions (“MI 61-101”).
  • The Los Santos Mine was acquired by Almonty in September 2011 and is located approximately 50 kilometres from Salamanca in western Spain and produces tungsten concentrate.
  • Almonty has also assumed that material factors will not cause any forward-looking statements and information to differ materially from actual results or events.
  • WHILE ALMONTY MAY ELECT TO, IT DOES NOT UNDERTAKE TO UPDATE THIS INFORMATION AT ANY PARTICULAR TIME EXCEPT AS REQUIRED IN ACCORDANCE WITH APPLICABLE LAWS.

pgEdge Distributed PostgreSQL Introduces Automatic DDL Replication and Snowflake Sequences for Postgres

Retrieved on: 
수요일, 4월 17, 2024
Cloud, DML, Table, Language, DELETE, CREATE, UPDATE, Documentation, Record, Silicon, GitHub, DDL, Snowflake, Database, ID, Data, Computer data storage

ALEXANDRIA, Va., April 17, 2024 /PRNewswire/ -- pgEdge, Inc., the leading company dedicated to distributed Postgres, today unveiled two major advances in logical replication for the widely adopted open-source PostgreSQL database. These are automatic DDL (Data Definition Language) replication, and snowflake sequences, an innovative solution to the problem of maintaining unique sequence identifiers across a distributed Postgres cluster. pgEdge Distributed PostgreSQL is the first and only fully distributed PostgreSQL database solution that is open (source available) and completely based on the PostgreSQL database itself.

Key Points: 
  • These are automatic DDL (Data Definition Language) replication, and snowflake sequences, an innovative solution to the problem of maintaining unique sequence identifiers across a distributed Postgres cluster.
  • pgEdge Distributed PostgreSQL is the first and only fully distributed PostgreSQL database solution that is open (source available) and completely based on the PostgreSQL database itself.
  • Traditionally, logical replication in Postgres only allowed for the replication of DML statements and not DDL.
  • Managing sequences in a distributed PostgreSQL environment can be complex, especially in multi-master replication scenarios.

ATHA Energy Provides Update on 2024 Exploration Program

Retrieved on: 
수요일, 3월 20, 2024
Diamond, Uranium, FRA, Kivalliq Region, Artemis program, National Instrument 43-101, Athabasca Basin, UPDATE, ANT, VLF, Mag, ASX, News, Acquisition, National instrument, Scheme, Discovery, EM, Probability, GMZ, Athabasca, Uranium mining

VANCOUVER, British Columbia, March 20, 2024 (GLOBE NEWSWIRE) -- ATHA Energy Corp. (TSX.V: SASK) (FRA: X5U) (OTCQB: SASKF) (“ATHA” or the “Company”), holder of the largest uranium exploration portfolio in two of the highest-grade uranium districts in the world, is pleased to announce plans for its 2024 Exploration Program. At the 100%-owned Angilak Project in Nunavut, the Company will focus on diamond drilling with the objective of deposit expansion and discovery. In the Athabasca Basin, the Company will be further advancing nine of its 100%-owned projects through a combination of ground and airborne geophysical surveys. The objective of the Athabasca Basin Program is to continue to mature ATHA’s geological understanding within each of its projects, increasing the probability of discovery and optimise capital expenditure during future drill campaigns. Additionally, subject to the completion of the Company’s proposed scheme of arrangement (the “Scheme”) with 92 Energy Limited (ASX: 92E) ("92E”), development of 92 Energy’s projects, such as Gemini, which hosts the recently discovered high-grade GMZ showing, will be incorporated into the into the Company’s Athabasca Basin Exploration Program. The Company will provide an update inclusive of drilling plans for the Gemini project, post closing of the Scheme.

Key Points: 
  • The objective of the 2024 Athabasca Basin Exploration Program is to advance ATHA’s exploration model, generating additional high-priority targets for future drill programs.
  • The Athabasca Basin Exploration Program is currently underway and is projected to continue through the end of Q3 2024.
  • VANCOUVER, British Columbia, March 20, 2024 (GLOBE NEWSWIRE) -- ATHA Energy Corp. (TSX.V: SASK) (FRA: X5U) (OTCQB: SASKF) (“ATHA” or the “Company”), holder of the largest uranium exploration portfolio in two of the highest-grade uranium districts in the world, is pleased to announce plans for its 2024 Exploration Program.
  • The 2024 Athabasca Basin Exploration Program is already underway and is slated to continue through to the end of Q3 2024.

Almonty Industries Inc. - Placement of Common Share Units and CDI’s raises C$1.47 million1 with Further Commitments of C$1.178 million for acceleration of Tungsten downstream planning and Molybdenum reserves conversion.

Retrieved on: 
토요일, 3월 23, 2024
Finance, Natural Resources, Professional Services, Other Natural Resources, Mining, Minerals, Indian stock exchange, Private placement, ANY, Private, CDI, APT, Minority, Risk, ASX, Sale, Acquisition, Placement, Lead, THIS, Tungsten, Moly, TSX, AII, ALI, Multilateral, UPDATE, Person

Proceeds from the Placement will be applied towards general working capital, including accelerating the downstream project planning and further investigation of the Moly due to increasing interest in the material domestically.

Key Points: 
  • Proceeds from the Placement will be applied towards general working capital, including accelerating the downstream project planning and further investigation of the Moly due to increasing interest in the material domestically.
  • The Placement Units and Placement CDI’s issued will rank equally with existing CDI’s and Common Shares on issue.
  • The closing of the CDI Placement is subject to receipt of all necessary regulatory approvals, including the acceptance by the TSX and ASX.
  • READERS SHOULD NOT PLACE UNDUE IMPORTANCE ON FORWARD- LOOKING INFORMATION AND SHOULD NOT RELY UPON THIS INFORMATION AS OF ANY OTHER DATE.

A Major Gas Find Could Upend European Energy Markets

Retrieved on: 
목요일, 3월 14, 2024
CVX, Kurdistan Region, Mobil, Molln, Natural gas, The Washington Post, ExxonMobil, Risk, Chevron Corporation, Knowledge, Cubic, Acquisition, Transport, XOM, Carbon, Eye, MCF, Investment, OMV, Hydrocarbon, Retirement, TALO, The Wall Street Journal, UPDATE, Economics, ConocoPhillips, Petroleum

LONDON, March 14, 2024 /PRNewswire/ -- As Europe realizes the full risk of relying on foreign oil and gas, it could soon find relief coming from an unexpected source. That's because, after years of leaning on cheap Russian gas, geopolitical shifts have changed the equation. Both the war in Ukraine and simple economics have forced the EU to pivot from strict green energy policies.  Companies mentioned in this release include: Chevron Corporation (NYSE: CVX), ExxonMobil Corporation (NYSE: XOM), ConocoPhillips (NYSE: COP), Talos Energy Inc. (NYSE: TALO), Cheniere Energy, Inc. (NYSE: LNG).

Key Points: 
  • '  And The Washington Post announced recently, 'Amid energy crisis, EU says gas can sometimes be 'green.''
  • The message is clear: Europe is scrambling to diversify its energy sources and achieve true energy independence.
  • That's why one Canadian energy company, MCF Energy ( MCF .V; MCFNF .QX), is on a mission to help secure Europe's energy independence and explore these long-ignored assets.
  • ConocoPhillips (NYSE: COP) has adeptly balanced its energy portfolio between natural gas and oil, reflecting a nuanced understanding of the world's changing energy consumption trends.

AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development

Retrieved on: 
목요일, 3월 7, 2024
Bias, Lung compliance, NON, SCIENCE, Tracheotomy, Acute myeloid leukemia, Mast cell activation syndrome, BTK, Alzheimer's disease, ANCOVA, Azacitidine, Missionary, B cell, Riluzole, CHMP, Guideline, NOD, Sickle cell disease, ALZ, Tablet, MECOM, AML, SCD, Biomarker, DSM-IV codes, Survival, Science, Prostate cancer, Oxygen, EMA, Docetaxel, Health Canada, ISM, FDA, Masitinib, Euronext, Cell, Chromosome abnormality, OS, UPDATE, Multiple sclerosis, COVID-19, Patient, Disease, Itch, RHU, CAFS, Failure, Depression, Pharmaceutical industry

SUMMARY OF THE WEBCAST HELD ON MARCH 4, 2024 PROVIDING AN UPDATE ON AB SCIENCE DEVELOPMENT

Key Points: 
  • SUMMARY OF THE WEBCAST HELD ON MARCH 4, 2024 PROVIDING AN UPDATE ON AB SCIENCE DEVELOPMENT
    AB Science SA (Euronext - FR0010557264 - AB) is providing a summary of the live webcast held on March 4, 2024, giving an update on AB Science development.
  • Regarding Health Canada, a Notice of Deficiency-Withdrawal (NOD/w) has been issued and AB Science intends to submit a Request for Reconsideration.
  • Based on the supporting arguments and counterarguments outlined above, AB Science intends to submit a Request for Reconsideration.
  • AB Science will be free to continue the development of masitinib in SCD based on phase 2 data with biomarkers.

Comstock Announces Full Year 2023 Results

Retrieved on: 
수요일, 2월 28, 2024
Engineering, NSR, Economic development, Commercialization, TRL, HBO, Mining, AI, Trade, Investment, Research, Sale, Biomass, Hyperspectral imaging, Carbon, Alfredo De Gasperis, UPDATE, Physics, Biorefinery, Gold, Metal, HRSI, Silver, LEO, Renewable energy

VIRGINIA CITY, Nev., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Comstock Inc. (NYSE: LODE) (“Comstock,” “our” and the “Company”), today announced its full year 2023 results, 2023 summary achievements, and our 2024 business outlook.

Key Points: 
  • VIRGINIA CITY, Nev., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Comstock Inc. (NYSE: LODE) (“Comstock,” “our” and the “Company”), today announced its full year 2023 results, 2023 summary achievements, and our 2024 business outlook.
  • “I just toured our recycling facility, with all equipment in place and pre-commissioning activities well underway,” stated Mr. De Gasperis.
  • “Our 2023 achievements were foundational and established a shared corporate services platform that enables speed for each of our business teams,” stated Mr. De Gasperis.
  • On June 30, 2023, the Company signed a Mineral Exploration and Mining Lease Agreement (the “Mining Lease”) with Mackay Precious Metals Inc. (“Mackay").

Jonathan Milner Issues Statement Responding to the Glass Lewis Report

Retrieved on: 
월요일, 10월 23, 2023
ACT, MAKE, ITS, TAX, FOR, PAST, FAIR, DATE, AS, UPDATE, SET, ANY, NO, AMERICA, FCA, EUROPEAN UNION, BY, FUTURE, FINANCIAL, III, TIME, UPON, NOT, EACH, AND, ALL, PER, THIS, OF, EXPRESS, AWARE, IS, NORTH, USE, IT, Glass fiber, Medical device, Audit, EU

T: +44 7733 265 198 / E: [email protected]

Key Points: 
  • T: +44 7733 265 198 / E: [email protected]
    T: +44 (0)20 3709 5700 / E: [email protected]
    T: +1 646 677 1811 / E: [email protected]
    THIS DOCUMENT HAS BEEN ISSUED BY DR. JONATHAN MILNER ("DR. MILNER").
  • DR. MILNER STRONGLY ADVISES ALL SHAREHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.
  • THE VIEWS EXPRESSED HEREIN REPRESENT THE OPINIONS OF DR. MILNER AS OF THE DATE HEREOF.
  • DR. MILNER HAS NOT SOUGHT OR OBTAINED CONSENT FROM ANY THIRD PARTY TO USE ANY STATEMENTS OR INFORMATION CONTAINED HEREIN.

Jonathan Milner Issues Statement Responding to ISS Report

Retrieved on: 
월요일, 10월 16, 2023
MAKE, ACT, III, AWARE, NO, AMERICA, NOT, PAST, TIME, DATE, THIS, AS, NORTH, USE, ANY, OF, IT, FOR, UPON, FINANCIAL, FCA, ITS, SET, IS, TAX, EXPRESS, EUROPEAN UNION, ALL, FAIR, UPDATE, BY, FUTURE, EACH, AND, Glass fiber, Medical device, Audit, EU

T: +44 7733 265 198 / E: [email protected]

Key Points: 
  • T: +44 7733 265 198 / E: [email protected]
    T: +44 (0)20 3709 5700 / E: [email protected]
    T: +1 646 677 1811 / E: [email protected]
    THIS DOCUMENT HAS BEEN ISSUED BY DR. JONATHAN MILNER ("DR. MILNER").
  • DR. MILNER STRONGLY ADVISES ALL SHAREHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.
  • THE VIEWS EXPRESSED HEREIN REPRESENT THE OPINIONS OF DR. MILNER AS OF THE DATE HEREOF.
  • DR. MILNER HAS NOT SOUGHT OR OBTAINED CONSENT FROM ANY THIRD PARTY TO USE ANY STATEMENTS OR INFORMATION CONTAINED HEREIN.